GENFIT to Participate in Upcoming Investor Conferences
05 Septembre 2023 - 10:10PM
GENFIT to Participate in Upcoming Investor Conferences
Lille (France), Cambridge
(Massachusetts, United States), Zurich
(Switzerland), September
05,
2023 – GENFIT (Nasdaq and
Euronext: GNFT), a late-stage biopharmaceutical company
dedicated to improving the lives of patients with rare and severe
liver diseases, today announced that it will participate in the
following upcoming investor conferences.
Morgan Stanley 21st Annual Global
Healthcare Conference Date: September 11-13, 2023Location:
New York
H.C. Wainwright 25th Annual Global
Investment Conference Date: September 11-13, 2023Date of
company presentation: September 12, 2023 at 9:30am ETLocation: New
York
Portzamparc BNP Paribas
Biotech & Health SeminarDate: October 4-5,
2023Format: Digital
Investor Access EventDate:
October 9-10, 2023Location: Paris
HealthTech Innovation DaysDate:
October 24-25, 2023Location: Paris
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company dedicated to
improving the lives of patients with rare and severe liver diseases
characterized by high unmet medical needs. GENFIT is a pioneer in
liver disease research and development with a rich history and
strong scientific heritage spanning more than two decades. Thanks
to its expertise in bringing early-stage assets with high potential
to late development and pre-commercialization stages, today GENFIT
boasts of a successful Phase III trial (ELATIVE®) evaluating
elafibranor in Primary Biliary Cholangitis (PBC) and a growing and
diversified pipeline of innovative therapeutic and diagnostic
solutions. Its R&D pipeline covers six therapeutic areas via
eight programs which explore the potential of differentiated
mechanisms of action, across a variety of development stages
(pre-clinical, Phase 1, Phase 2, Phase 3). These diseases are acute
on chronic liver failure (ACLF), hepatic encephalopathy (HE),
cholangiocarcinoma (CCA), urea cycle disorders (UCD), organic
acidemias (OA) and PBC. Beyond therapeutics, GENFIT’s pipeline also
includes a diagnostic franchise focused on NASH and ACLF. GENFIT
has facilities in Lille and Paris (France), Zurich (Switzerland)
and Cambridge, MA (USA). GENFIT is a publicly traded company listed
on the Nasdaq Global Select Market and on compartment B of
Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT).
In 2021, IPSEN became one of GENFIT’s largest shareholders and
holds 8% of the company’s share capital. For more information,
visit www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain
forward-looking statements with respect to GENFIT, including those
within the meaning of the Private Securities Litigation Reform Act
of 1995 in relation to GENFIT’s research and development programs.
The use of certain words, including “consider”, “contemplate”,
“think”, “aim”, “expect”, “understand”, “should”, “aspire”,
“estimate”, “targeted”, “anticipated”, “believe”, “wish”, “may”,
“could”, “allow”, “seek”, “encourage” or “have confidence” or (as
the case may be) the negative forms of such terms or any other
variant of such terms or other terms similar to them in meaning is
intended to identify forward-looking statements. Although the
Company believes its projections are based on reasonable
expectations and assumptions of the Company’s management, these
forward-looking statements are subject to numerous known and
unknown risks and uncertainties, which could cause actual results
to differ materially from those expressed in, or implied or
projected by, the forward-looking statements. These risks and
uncertainties include, among other things, the uncertainties
inherent in research and development, including in relation to
safety, biomarkers, cost of, progression of, and results from, its
ongoing and planned clinical trials, review and approvals by
regulatory authorities in the United States, Europe and worldwide
of our drug and diagnostic candidates, potential commercial success
of elafibranor if approved, exchange rate fluctuations, potential
synergies related to the acquisition of Versantis, our capacity to
integrate its assets, develop its programs and our continued
ability to raise capital to fund our development, as well as those
risks and uncertainties discussed or identified in the Company’s
public filings with the AMF, including those listed in Chapter 2
“Main Risks and Uncertainties” of the Company’s 2022 Universal
Registration Document filed with the Autorité des marches
financiers (AMF) on April 18, 2023, which is
available on the Company’s website (www.genfit.com) and on the
website of the AMF (www.amf-france.org) and public filings and
reports filed with the U.S. Securities and Exchange Commission
(“SEC”) including the Company’s 2022 Annual Report
on Form 20-F filed with the SEC on April 18, 2023. In addition,
even if the Company’s results, performance, financial condition and
liquidity, and the development of the industry in which it operates
are consistent with such forward-looking statements, they may not
be predictive of results or developments in future periods. These
forward-looking statements speak only as of the date of publication
of this document. Other than as required by applicable law, the
Company does not undertake any obligation to update or revise any
forward-looking information or statements, whether as a result of
new information, future events or otherwise.
CONTACT
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
GENFIT | Press relations
Stephanie Boyer | Tel: +33 3 2016 4000 |
stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos -
FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT to Participate in Upcoming Investor Conferences
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024